Growth Hormone Insensitivity Syndrome (GHIS); Clinical Presentation and Effects of Treatment with Recombinant Human Insulin-like Growth Factor I (rhIGF-I) European Experience

Martin O. Savage, Werner F. Blum, Pierre G. Chatelain, Michael A. Preece, Michael B. Ranke, Ronald (Ron) Rosenfeld, Patric Wilton

Research output: Contribution to journalArticle

Abstract

Growth hormone insensitivity syndrome (GHIS) is a pathological state characterised by disturbance of the normal relationships between growth hormone (GH) secretion, insulin-like growth factor I (IGF-I) synthesis and GH action. Laron syndrome (LS) is the most severe form and is related to defects of the GH receptor gene. Twenty-seven cases of LS from 8 European countries and Australia were characterised clinically and endocrinologically. Clinical features (median) were; age 2.8-22.6 years, 12 males, 15 females, birth weight-0.72 SDS, birth length-1.59 SDS. Hypoglycemia occurred in 33 % and micropenis in 58 % of males. Height was-6.0 SDS, weight-3.2 SDS, % weight for height 111.3. Bone age was delayed in 19 of the 27 patients. Endocrine values (median) were; GH 17 [igL, IGF-I < 5th centile, with % increment during IGF-I generation test < 20%. IGFBP-3 was < 5th centile, GH-BP was low or undetectable in 20 and normal in 7 subjects. Treatment with recombinant IGF-I offered the only form of effective therapy. Treatment of 13 patients with IGF-I, 120 (ig/kg bid induced a change in mean height velocity from 4.1 cm/year before treatment to 10.2 cm/year at 6 months and 8.8 cm/year at 12 months. Adverse effects were minimal. Facial appearance showed a change in maturity associated with capital hair growth. Further studies to define the optimum dose regimen of IGF-I are in progress.

Original languageEnglish (US)
Pages (from-to)115-121
Number of pages7
JournalClinical Pediatric Endocrinology
Volume3
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

Laron Syndrome
Insulin-Like Growth Factor I
Growth Hormone
Therapeutics
Weights and Measures
Insulin-Like Growth Factor Binding Protein 3
Hypoglycemia
Birth Weight
Hair
Economics
Parturition
Bone and Bones
Growth

Keywords

  • growth hormone insensitivity
  • IGF-I therapy
  • Laron syndrome

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Growth Hormone Insensitivity Syndrome (GHIS); Clinical Presentation and Effects of Treatment with Recombinant Human Insulin-like Growth Factor I (rhIGF-I) European Experience. / Savage, Martin O.; Blum, Werner F.; Chatelain, Pierre G.; Preece, Michael A.; Ranke, Michael B.; Rosenfeld, Ronald (Ron); Wilton, Patric.

In: Clinical Pediatric Endocrinology, Vol. 3, 1994, p. 115-121.

Research output: Contribution to journalArticle

Savage, Martin O. ; Blum, Werner F. ; Chatelain, Pierre G. ; Preece, Michael A. ; Ranke, Michael B. ; Rosenfeld, Ronald (Ron) ; Wilton, Patric. / Growth Hormone Insensitivity Syndrome (GHIS); Clinical Presentation and Effects of Treatment with Recombinant Human Insulin-like Growth Factor I (rhIGF-I) European Experience. In: Clinical Pediatric Endocrinology. 1994 ; Vol. 3. pp. 115-121.
@article{46b669b60b9f478e91d36929a741250e,
title = "Growth Hormone Insensitivity Syndrome (GHIS); Clinical Presentation and Effects of Treatment with Recombinant Human Insulin-like Growth Factor I (rhIGF-I) European Experience",
abstract = "Growth hormone insensitivity syndrome (GHIS) is a pathological state characterised by disturbance of the normal relationships between growth hormone (GH) secretion, insulin-like growth factor I (IGF-I) synthesis and GH action. Laron syndrome (LS) is the most severe form and is related to defects of the GH receptor gene. Twenty-seven cases of LS from 8 European countries and Australia were characterised clinically and endocrinologically. Clinical features (median) were; age 2.8-22.6 years, 12 males, 15 females, birth weight-0.72 SDS, birth length-1.59 SDS. Hypoglycemia occurred in 33 {\%} and micropenis in 58 {\%} of males. Height was-6.0 SDS, weight-3.2 SDS, {\%} weight for height 111.3. Bone age was delayed in 19 of the 27 patients. Endocrine values (median) were; GH 17 [igL, IGF-I < 5th centile, with {\%} increment during IGF-I generation test < 20{\%}. IGFBP-3 was < 5th centile, GH-BP was low or undetectable in 20 and normal in 7 subjects. Treatment with recombinant IGF-I offered the only form of effective therapy. Treatment of 13 patients with IGF-I, 120 (ig/kg bid induced a change in mean height velocity from 4.1 cm/year before treatment to 10.2 cm/year at 6 months and 8.8 cm/year at 12 months. Adverse effects were minimal. Facial appearance showed a change in maturity associated with capital hair growth. Further studies to define the optimum dose regimen of IGF-I are in progress.",
keywords = "growth hormone insensitivity, IGF-I therapy, Laron syndrome",
author = "Savage, {Martin O.} and Blum, {Werner F.} and Chatelain, {Pierre G.} and Preece, {Michael A.} and Ranke, {Michael B.} and Rosenfeld, {Ronald (Ron)} and Patric Wilton",
year = "1994",
doi = "10.1297/cpe.3.Supple5_115",
language = "English (US)",
volume = "3",
pages = "115--121",
journal = "Clinical Pediatric Endocrinology",
issn = "0918-5739",
publisher = "Jeff Corporation Co. Ltd",

}

TY - JOUR

T1 - Growth Hormone Insensitivity Syndrome (GHIS); Clinical Presentation and Effects of Treatment with Recombinant Human Insulin-like Growth Factor I (rhIGF-I) European Experience

AU - Savage, Martin O.

AU - Blum, Werner F.

AU - Chatelain, Pierre G.

AU - Preece, Michael A.

AU - Ranke, Michael B.

AU - Rosenfeld, Ronald (Ron)

AU - Wilton, Patric

PY - 1994

Y1 - 1994

N2 - Growth hormone insensitivity syndrome (GHIS) is a pathological state characterised by disturbance of the normal relationships between growth hormone (GH) secretion, insulin-like growth factor I (IGF-I) synthesis and GH action. Laron syndrome (LS) is the most severe form and is related to defects of the GH receptor gene. Twenty-seven cases of LS from 8 European countries and Australia were characterised clinically and endocrinologically. Clinical features (median) were; age 2.8-22.6 years, 12 males, 15 females, birth weight-0.72 SDS, birth length-1.59 SDS. Hypoglycemia occurred in 33 % and micropenis in 58 % of males. Height was-6.0 SDS, weight-3.2 SDS, % weight for height 111.3. Bone age was delayed in 19 of the 27 patients. Endocrine values (median) were; GH 17 [igL, IGF-I < 5th centile, with % increment during IGF-I generation test < 20%. IGFBP-3 was < 5th centile, GH-BP was low or undetectable in 20 and normal in 7 subjects. Treatment with recombinant IGF-I offered the only form of effective therapy. Treatment of 13 patients with IGF-I, 120 (ig/kg bid induced a change in mean height velocity from 4.1 cm/year before treatment to 10.2 cm/year at 6 months and 8.8 cm/year at 12 months. Adverse effects were minimal. Facial appearance showed a change in maturity associated with capital hair growth. Further studies to define the optimum dose regimen of IGF-I are in progress.

AB - Growth hormone insensitivity syndrome (GHIS) is a pathological state characterised by disturbance of the normal relationships between growth hormone (GH) secretion, insulin-like growth factor I (IGF-I) synthesis and GH action. Laron syndrome (LS) is the most severe form and is related to defects of the GH receptor gene. Twenty-seven cases of LS from 8 European countries and Australia were characterised clinically and endocrinologically. Clinical features (median) were; age 2.8-22.6 years, 12 males, 15 females, birth weight-0.72 SDS, birth length-1.59 SDS. Hypoglycemia occurred in 33 % and micropenis in 58 % of males. Height was-6.0 SDS, weight-3.2 SDS, % weight for height 111.3. Bone age was delayed in 19 of the 27 patients. Endocrine values (median) were; GH 17 [igL, IGF-I < 5th centile, with % increment during IGF-I generation test < 20%. IGFBP-3 was < 5th centile, GH-BP was low or undetectable in 20 and normal in 7 subjects. Treatment with recombinant IGF-I offered the only form of effective therapy. Treatment of 13 patients with IGF-I, 120 (ig/kg bid induced a change in mean height velocity from 4.1 cm/year before treatment to 10.2 cm/year at 6 months and 8.8 cm/year at 12 months. Adverse effects were minimal. Facial appearance showed a change in maturity associated with capital hair growth. Further studies to define the optimum dose regimen of IGF-I are in progress.

KW - growth hormone insensitivity

KW - IGF-I therapy

KW - Laron syndrome

UR - http://www.scopus.com/inward/record.url?scp=85004571175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85004571175&partnerID=8YFLogxK

U2 - 10.1297/cpe.3.Supple5_115

DO - 10.1297/cpe.3.Supple5_115

M3 - Article

AN - SCOPUS:85004571175

VL - 3

SP - 115

EP - 121

JO - Clinical Pediatric Endocrinology

JF - Clinical Pediatric Endocrinology

SN - 0918-5739

ER -